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ABSTRACT 
 
       MicroRNAs (miRNAs) are non-coding small RNAs that regulate eukaryotic gene 
activity at the post-transcriptional level by a process termed miRNA gene suppression.  
MicroRNA-122 (miR-122) is predominantly expressed in human liver cells and recent 
studies indicated that miR-122 promotes Hepatitis C Virus (HCV) replication and 
translation through physical interaction with two tandem binding sites located in the 5’ 
untranslated region (5’UTR) of the HCV genome (Jopling, et al., 2006; Jopling, et al., 
2008). It has been reported that host genes that are also implicated in the miRNA gene 
suppression pathway are key regulators of HCV replication (Randall, et al., 2007). Two 
proteins, Dicer, a key RNaseIII enzyme, and its binding partner TRBP are essential 
proteins for miRNA activity.  They are part of a protein complex called the RNA induced 
silencing complex (RISC) which also includes Argonaute proteins, and function in    
miRNA biogenesis loading the miRNA into RISC.  As such, they are  intriguing targets 
to study host-viral interplay during HCV replication. 
      In our study, we designed siRNAs to knock down Dicer and TRBP and then observed 
the effects of gene knockdown on full length J6/JFH-1-RLuc HCV (genotype 2a chimeric 
genome) replication and translation. The results showed that knocking down Dicer and 
TRBP reduced wild type (wt) J6/JFH-1-RLuc replication but had almost no effects on 
HCV translation in human liver cells. However, since knocking down Dicer and TRBP 
did not significantly alter miR-122 levels in the cell, it appears that the role of Dicer and 
TRBP was not solely the biogenesis of miR-122.  This was confirmed by an experiment 
in which we observed that knocking down Dicer and TRBP also attenuated replication of 
ii 
 
a mutant virus in which replication is dependent on a exogenously supplied miRNA 
instead of endogenous miR-122.                    
      Taken together, the results supported the hypotheses that Dicer and TRBP facilitate 
HCV infection mainly through HCV replication but not translation.  The effects of Dicer 
and TRBP on HCV replication are not solely due to miR-122 biogenesis, and may be due 
to RISC loading functions in steps of miRNA gene suppression.  
       This study has set some essential groundwork for investigating potential roles of host 
factors in the RNAi machinery modulating HCV replication/translation and exploring 
novel antiviral targets.  
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1.0 INTRODUCTION 
       1.1 Hepatitis C 
The disease caused by Hepatitis C virus (HCV) was first observed in the 1970s 
and was characterized as post-transfusion hepatitis that was not caused by Hepatitis A or 
B virus (thus termed non-A and non-B hepatitis).  Hepatitis C virus was identified as the 
cause of this disease by using recombinant DNA technology in 1989 (Choo, et al. 1989), 
since then, HCV has been recognized as a major cause of chronic liver disease and affects 
nearly 200 million people worldwide. In Canada, about 250,000 people are currently 
infected, and nearly 8000 individuals become newly infected each year (http://www.hc-
sc.gc.ca/hl-vs/iyh-vsv/diseases-maladies/hepc-eng.php). Persistent HCV infection is 
associated with the development of chronic hepatitis, hepatic steatosis, cirrhosis, and 
hepatocellular carcinoma. In general, HCV infection results in an acute infection which is 
asymptomatic and often undiagnosed. Approximately 15-20% of acutely infected patients 
are able to self-clear the infection without mediation. However, in the majority of cases, 
acute infection becomes chronic. Approximately one-fifth of chronically infected 
individuals progress to cirrhosis over a 5-30 year period and a small number of 
individuals develop hepatocellular carcinoma (Chen, et al., 2006). HCV is generally 
transmitted through blood transfusions, hemodialysis, organ transplants, and sharing of 
needles (Lauer, et al., 2001).   
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      1.2 HCV Therapeutics 
So far the development of anti-HCV vaccines has been unsuccessful mainly due 
to the genetic variability of HCV which allows the virus to rapidly escape immune 
surveillance. Current clinical treatments against HCV infections are limited to a 
combined administration of pegylated interferon (INF)-α and ribavirin. However, this 
standard treatment regimen assures a long term eradication of HCV in less than half of 
infected patients and results in considerable side effects that include depression, 
hemolytic anemia, fever and chills, and produces different sustained viral response rates 
among different genotypes (Qureshi, et al., 2007). Moreover, the clinical development of 
novel antiviral drugs targeting HCV protein processing and replication is progressing 
more slowly than expected due to safety issues and viral resistance  (Pawlotsky, et al., 
2007). Thus, a detailed understanding of virus-host interaction during HCV infection may 
provide opportunities to develop alternative and more effective approaches to overcome 
viral resistance which will complement current antiviral therapies.  
Our studies on virus-host interactions focus on the relationship between HCV 
infection and the host miRNA pathway.  Several lines of evidence indicate that the 
miRNA pathway influences HCV replication.  Results of a systematic RNA interference 
(RNAi) screen demonstrated that various cellular proteins, including essential 
components of the RNA interference pathway, were able to alter HCV infection (Randall, 
et al., 2007). At the same time, our lab had also discovered that depletion of Argonaute 2, 
a central effector of miRNA activity, affected HCV replication (unpublished).  In 
addition, a liver specific micro RNA, miR-122, was identified to bind to a region within 
the 5’UTR (Figure 1-1) and facilitate HCV RNA accumulation and translation through 
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unknown mechanisms (Jopling, et al., 2006; Jopling, et al., 2008; Henke, et al., 2008). 
Moreover, there is growing evidence that the reason why the host liver environment is 
highly permissive for HCV replication might be due to high levels of  microRNA-122 
(miR-122),  and the host may specifically alter miR-122 levels as a mechanism to resist 
HCV replication as levels of miR-122 were downregulated following INF-β treatment 
(Pedersen, et al.,  2007). Therefore, we were inspired to further explore the mechanisms 
of miRNA pathway enhancement of HCV replication, particularly focusing on proteins 
involved in the processing and activity of miRNAs, Dicer and TRBP, with the goal of 
identifying novel antiviral targets.  
 
      1.3 Hepatitis C Virus  
 
 HCV belongs to Hepacivirus genus within the Flaviviridae family. The virus 
exists as six major genotypes, each being defined by their nucleotide sequences, which 
may differ by up to 30-35%.  Each genotype is also divided into several subtypes 
(represented by letters) based on sequence differences (Moradpour, et al., 2007).  HCV 
genotypes have varied geographical distributions with genotype 1, 2, and 3 being widely 
distributed throughout Western countries and the Far East (Japan, China, Taiwan, and 
Thailand). Type 5 and 6 are the most prevalent in South Africa and Southeast Asia, 
respectively. Type 4 is predominant in the Middle East and Central Africa (McOmish, et 
al., 1994).  HCV is a spherical, enveloped virus 40-70 nm in diameter, with a narrow host 
range consisting of human and chimpanzees. HCV contains a 9.6 kb linear positive 
single-stranded RNA genome that encodes a single open reading frame (ORF), flanked 
by 5′ and 3′ untranslated regions (UTRs) (Farci, et al., 2002).  The 5’and 3’UTRs are the 
most conserved regions of HCV RNA and play key roles in regulating translation and 
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RNA replication. The 5’ UTR contains a highly conserved internal ribosome entry 
sequence (IRES) onto which the 40S ribosomal subunit binds to initiate polyprotein 
translation in a cap-independent manner (Spahn, et al., 2001). The 3’ UTR is composed 
of a short variable region, a poly (U/UC) tract with average length of 80 nt, and a highly 
conserved 98 nt X-tail region all of which are essential for viral replication (Tanaka, et al., 
1996). 
 
 
Figure 1-1: Genetic organization of HCV RNA genome (Jopling, et al., 2006). 
The HCV genome is shown with the polyprotein ORF coding for the structural and the non-
structural replication protein, the 5’ and 3’UTRs. Sequences in the 5’UTR complementary to 
miR-122 are shown as grey boxes. 
 
    1.4 HCV Lifecycle: 
           1.4.1Attachment and Entry   
HCV infection is a highly dynamic process with a virion half-life of only a few 
hours. HCV virions circulate in three forms, in physical association with very-low-
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density lipoprotein (VLDL), or low-density lipoprotein (LDL);   as free virions, or virions 
bound to immunoglobulins (Andre et al. 2005). Entry into hepatocytes requires multiple 
cell surface protein receptors: the tetraspanin CD81 (Pileri, et al. 1998), the scavenger 
receptor class B type I (SR-BI) (Scarselli, et al. 2002), and the tight junction proteins 
claudin-1 (Evans, et al. 2007) and occludin (Ploss, et al. 2009). HCV entry is also 
facilitated by additional receptor components, such as glycosaminoglycans, the LDL 
receptor, and the lectins DC-SIGN and L-SIGN, however, these are not essential entry 
factors and do not confer tissue specificity (Lozach, et al. 2003;  Saunier, et al. 2003; 
Agnello, et al. 1999). Once attached, HCV is internalized via clathrin-mediated 
endocytosis and the viral nucleic acids are released into the host cell cytoplasm, 
following acidification of early endosomes (Evans, et al. 2007).  
 
       1.4.2 IRES Mediated Translation Initiation  
HCV translation is the first macromolecular synthetic event after the HCV 
genome is released into the cytosol. In contrast to eukaryotic protein synthesis in which 
translation initiation involves cap-dependent scanning to arrest the start codon with 
canonical initiation factors, the naturally uncapped viral RNA genomes of HCV are 
translated via a cap-independent IRES-mediated mechanism.  Initiation of IRES 
translation follows direct recruitment of ribosomes to the site of translation initiation with 
only a minimal requirement for canonical translation apparatus (Tsukiyama-Kohara, et al. 
1992). The HCV 5’UTR comprises 341 nucleotides upstream of the translation initiation 
codon and contains four highly structured RNA domains (I-IV). Domains II, III, and IV, 
together with the first 24-40 nts of the core-encoding region, constitute the IRES 
5 
 
(Moradpour, et al., 2007). IRES-mediated translation is initiated by direct binding of the 
40S ribosomal subunit to the HCV IRES. The IRES-40S ribosome complex sequentially 
recruits eukaryotic initiation factor eIF3 to stabilize ternary complex Met-tRNA-eIF2-
GTP, resulting in the formation of a 48S rRNA complex at the AUG initiation codon. 
Finally, the 60S subunit is recruited to form an active 80S complex in a GTP hydrolysis 
step (Fraser, et al., 2007; Hellen, et al., 2009).  
Translation of the HCV ORF yields a single polyprotein of approximately 3,000 
amino acids. The polyprotein is co- and posttranslationally processed by cellular and viral 
proteases into at least 10 structural and nonstructural proteins (NS) (De Francesco, et al., 
2000). The structural proteins, which form the viral particles, include core, and the two 
envelope glycoproteins E1 and E2.  The non-structural proteins include  p7, an ion 
channel;  NS2-3, a protease; NS3, a serine protease and RNA helicase;  NS4A;  NS4B;  
NS5A, and NS5B, an RNA-dependent RNA polymerase (RdRp) (Fraser, et al., 2007) 
(Figure 1-1).  
 
       1.4.3 RNA Replication 
HCV translation and replication occurs in association with intracellular 
membranes. Infection with HCV leads to visible alterations to host cellular ER 
membranes to form what is termed a “membranous web” (Egger, et al., 2002).  The 
replication complex, composed of viral proteins, cellular components, and replicating 
RNA (Egger, et al., 2002) was identified as being specifically located within the 
membranous web (Gosert, et al., 2003). So far, the precise mechanisms of HCV 
replication are still poorly defined. As with other positive-strand RNA viruses, HCV 
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replication is assumed to be performed in two semiconservative and asymmetric steps, 
catalyzed by NS5B RdRp. It starts with the synthesis of a complementary negative-strand 
intermediate by using the viral genomic RNA as a template. In the second step, (-) strand 
RNA is used as a template to produce numerous strands of positive polarity, which is 
transcribed at a level in 5- to 10- fold excess compared with (-) RNA.  Nascent (+) viral 
RNAs are subsequently subjected to polyprotein translation, synthesis of new 
intermediates of replication, or packaging into new virus particles (Suzuki, et al., 2007). 
In recent studies, Jopling et al. found that highly abundant and liver-specific microRNA-
122 binds to a region within the 5’UTR and facilitates HCV replication through unknown 
mechanisms (Jopling, et al., 2006; Jopling, et al., 2008).  
 
       1.4.4 Virus Assembly and Release 
Much has been learned about HCV assembly and release since the development 
of an efficient cell culture model system for HCV in 2005. Based on current evidence, 
assembly initiates on the cytosolic side of the ER membrane and maturation is completed 
in the ER lumen prior to release from host cells. In the early step of assembly, progeny 
genomes are released from the membranous web and moved to specialized lipid droplets 
(LDs).  LDs are coated with viral proteins (Miyanari, et al., 2007; Boulant, et al., 2007), 
which permits the encapsidation of the HCV genomes and the formation of the 
nucleocapsids. Core and NS5A associate with each other and with LDs (Masaki, et al., 
2008), which is crucial for the trafficking of viral replication complexes and RNA to LDs 
for virus production. NS3 is also recruited to LDs and it is predicted to be important for a 
stage in virus assembly after the interaction between core and NS5A at LD surfaces but 
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prior to assembly of core-containing particles (Ma, et al., 2008).  Late assembly steps 
involve the acquisition of a lipid envelope and the incorporation of the E1/E2 
glycoproteins into virions (Jones, et al., 2010). NS2 appears to confer infectivity to 
virions.  They are thought to bridge glycoproteins and nascent particles together to form 
fully infectious HCV virions (Jones, et al., 2007). There is an expanding list of viral NSs 
that are predicted to engage in the process of assembly and release of HCV, such as p7 
(without the precise knowledge at which stage p7 is involved) (Steinmann, et al., 2007) 
and NS4B, which is suggested to regulate virus production through its regulatory 
functions on other replicase components to increase delivery of genomes to packing sites 
(Jones, et al., 2009). Current models suggest that maturation and egress of HCV virions 
occur in concert with the production of very low density lipoproteins vLDL (Huang, et al., 
2007).  VLDL is a family of spherical particles that are produced only in liver to export 
triglyceride and cholesterol into plasma, and their production is a major function of 
hepatocytes (Gibbons, et al., 2004). During maturation, nascent viral particles become 
complexed with pre-vLDL; lipids, in the form of lumenal LDs; and other lipoprotein 
components, such as apoE (Boulant, et al., 2007) to generate lipoviroparticles (LVP) that 
are then released from the cell (Gibbons, et al., 2004).  Knowledge about HCV assembly 
and release is increasing, with study in this area is still in its early stages, but rapidly 
progressing.  
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Figure 1-2 Lifecycle of HCV 
 (http://www.tibotec.com/content/backgrounders/www.tibotec.com/hcv_lifecycle.html).  
(A): Virus binding by HCV receptors/co-receptors and internalization by endocytosis. (B): 
Cytoplasmic release from early endosomes and uncoating the viral RNA genome into cells.  (C): 
IRES-mediated translation and polyprotein processing by cellular and viral proteases at ER 
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membrane. (D): HCV RNA replication occurs in the membranous web. Once there is adequate 
viral RNA transcriptase, + strand viral RNA serves as a template to generate – strand RNA 
intermediates and make the genetic materials for new viruses. (E): Packaging and assembly. 
 
      1.5 HCV Model Replication Systems----The HCV Replicon 
The first breakthrough allowed detailed molecular studies of HCV replication, 
pathogenesis, and evolution in cell culture was the development of the HCV replicon 
system. The prototype subgenomic selectable replicon is a bicistronic RNA which 
encodes an authentic HCV 5’ UTR, a neomycin phosphotransferase gene, a second IRES 
element from Encephalomyocarditis virus (EMCV) that drives translation of the non-
structural proteins 3-5B, followed by the HCV 3’UTR (Lohmann, et al., 1999). Cells in 
which this RNA can replicate are selected by their ability to grow following selection 
with G418. In subsequent studies, full-length replicons and HCV genomes that replicate 
efficiently in a wide range of permissive host cells have been established. However, the 
latter stages of the virus life cycle including virion assembly and release were not 
amenable for detailed study until the discovery of HCV JFH-1.  JFH-1 HCV (genotype 
2a) was isolated from a Japanese patient with a rare case of fulminant hepatitis C and it 
was found to replicate in Huh-7 and other cell lines without the requirement for adaptive 
mutations, and produced infectious virions that could infect naïve Huh-7 cells (Kato, et 
al., 2003). Infectivity was enhanced by using highly permissive Huh-7 sub-lines (Zhong, 
et al., 2005) and chimaeric clones that consisted of the 5’ and 3’ UTRs, as well as NS3-
5B regions of JFH-1 and the C terminus of NS2 protein of a different genotype 2a isolate 
designated J6 (Pietschmann, et al., 2006). HCVcc (for HCV cell culture) strain FL 
10 
 
J6/JFH-1 can develop long term infection in chimpanzees and in immunodeficient mice 
engrafted with human liver tissue. Viral inocula derived from these animal models were 
infectious for naive Huh-7 cells (Lindenbach, et al., 2006). Therefore, 17 years after the 
identification of HCV, the utility of the cell-culture-derived HCV (HCVcc) genetic 
system opened a new era for investigating the complete in vitro and in vivo HCV 
lifecycle, and analyzing the essential contribution of host cell factors to virus production. 
We are particularly interested in using these systems to study the interactions between the 
host miRNA pathway and HCV replication and translation. 
 
      1.6 MicroRNA and HCV Infection 
            1.6.1 MicroRNA Pathway 
MicroRNAs (miRNAs) are non-coding small RNAs that regulate eukaryotic gene 
activity at the post-transcriptional level by inhibiting mRNA translation.  More than 1000 
miRNAs are expressed in mammals and are initially encoded as part of large precursor 
transcripts called primary miRNAs (pri-miRNA).  Pri-miRNAs are processed  into~60-70 
nt hairpin precursor miRNAs (pre-miRNA) within the nucleus by a multiprotein complex 
called the Microprocessor, mainly composed of an RNase III enzyme, Drosha and the 
double-stranded RNA-binding domain (dsRBD) protein, DGCR8 (Denli, et al., 2004; 
Gregory, et al., 2004; Han, et al., 2004).  Pre-miRNAs are exported to the cytoplasm by 
exportin-5 (Bohnsack, et al., 2004), where they are further processed by the cytoplasmic 
endonuclease III enzyme Dicer, with assistance by its binding partners, named human 
immunodeficiency virus 1 (HIV-1) transactivating response (TAR) RNA-binding protein 
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(TRBP) (Gatignol, et.al., 1991) and protein activator of PKR (PACT) (Kok, et al., 2007; 
Lee, et al., 2006).  The result is a ~22 nt long miRNA duplex bearing 2-nt overhangs at 
both 3’ ends. Following miRNA processing, Dicer and TRBP function to integrate the 
newly synthesized miRNA into a trimeric protein complex containing Ago2, Dicer, and 
TRBP, a complex also termed the RNA-induced silencing complex (RISC), a 
ribonucleoprotein (RNP) complex. Once incorporated into RISC, the mature miRNA is 
unwound and guides RISC to complementary target sites in the 3' untranslated region (3' 
UTR) of messenger RNAs. On the basis of the degree of complementarities between the 
miRNA and the mRNA, RISC inhibits translation by an unknown mechanism.  In some 
cases miRNA binding also alters mRNA stability (Gregory, et al., 2005; Bushati, et al., 
2007) (Figure 1-3).  
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Figure 1-3: miRNA guided RNA interference in mammalian cells. 
The endogenous mammalian miRNA pathway: begins with endogenous host primary mRNAs 
(pri-mRNAs) that are processed by the Drosha/DGCR8 complex to yield ~60-70 nt precursor 
miRNAs (pre-miRNAs). These hairpin-shaped pre-miRNAs are then exported to the cytoplasm 
by Exportin 5 and subsequently processed into ~22 nt mature miRNA duplex by Dicer and its 
partners TRBP and PACT.  Dicer and TRBP then load the guide strand with lower stability in the 
5’ end is loaded into Ago2.  MiRNAs can guide RISC to 3’ UTR of complementary mRNAs. On 
the basis of the degree of homology between the miRNAs and the mRNAs, RISC can inhibit 
mRNAs function by inhibiting their translation. 
 
It has been well established that miRNAs are involved in many basic physiologic 
processes including cell growth, tissue differentiation, embryonic development, cell 
proliferation and apoptosis. MiRNAs control various biological processes, including cell 
differentiation, cell proliferation, apoptosis, stress resistance, and fat metabolism (Hwang, 
et al., 2006;  Ambros et al., 2003; Harfe, et al., 2005). Cellular miRNAs are not only 
implicated in immune cell development and function (Lindsay, et al., 2008), but are also 
directly implicated in defense against viral infections. In addition, some DNA viruses 
express miRNAs, such as herpesvirus, adenovirus, retrovirus and polyomavirus families 
(Cullen, et al., 2006), and some are reported to suppress the innate immune response to 
promote virus growth (Lindsay, et al., 2008). Certain miRNAs are expressed ubiquitously, 
whereas others exhibit a high level of specificity of expression, both according to tissue 
type, developmental stage, and cancer (Bushati, et al., 2007).  MiR-122 is found 
specifically in mouse, woodchuck and human liver, human primary hepatocytes, and in 
cultured liver-derived cells, such as human hepatcellular carcinoma cell line 7 (Huh 7) 
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(Girard, et al., 2008; Jopling, et al., 2005). In human liver cells, miR-122 is identified to 
account for approximate 70% of the total liver miRNA population and expressed at a 
high level with more than 66,000 copies per cells (Jopling, et al., 2005; Girard, et al., 
2008).  
 
            1.6.2 The Influence of miR-122 on HCV Replication 
Seemingly intrigued by the tissue-specific nature of miR-122, Jopling and co-
workers investigated its influence on HCV replication.  They found that sequestering 
endogenous miR-122 in Huh-7 cells by antisense oligonucleotiedes (ASOs), which is 
able to completive bind to endogenous miR-122,  caused a reduction of HCV RNA 
abundance at 48h post transfection, leading to their conclusion that miR-122 may 
stimulate HCV replication (Jopling, et al., 2006). By introducing mutations to the HCV 5’ 
UTR and complementing miR-122 with compensatory mutations, the authors clearly 
demonstrated  that the effects of miR-122 on  HCV RNA abundance was through 
physical interactions of miR-122 with two tandem miR-122 binding sites located between 
stem-loops I and II of the highly conserved 5’ UTR of HCV (Jopling, et al.,  2008) 
(Figure 1-1).  
In a recent study, Henke et al. (2008) identified that the interaction of miR-122 
with the HCV 5’ UTR also stimulated HCV translation at an early stage of HCV 
infection. MiR-122 was detected in the 48S translation initiation complexes with the 
HCV RNA. Moreover, the interaction between mutated miR-122 binding sites and the 
corresponding mutated miR-122 led to a strong stimulation in ribosome association in 
HeLa cells. The translation stimulation was observed even with an NS5B-polymerase 
defective genome. Supplement to Jopling’s and Henke’s work, Jangra et al. confirmed 
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the ability of miR-122 to promote the growth of infectious virus, including HCV 
replication and  translation through direct interaction with both seed-sequence-binding 
sites (S1, S2) by studying  virus infectivity using an infectious HCV strain (HJ3-5 virus). 
The S1 site appears to be more important for efficient replication than binding to the 
downstream S2 site, and the contribution of each binding site seems equally important for 
HCV translation, as shown by mutating the binding sites and supplementing with 
complementary mutant forms of miR-122. However, the positive regulation of miR-122 
on HCV translation is insufficient to support the striking enhancement of HCV genome 
amplification and virus production. As an IRES mutant genome with a quantitatively 
equivalent defect in translation generated much better viral production than that of 
double-binding-site mutant genome. Thus, their study predicted that miR-122 is likely to 
act to stimulate both replication and translation (Jangra, et al., 2010). 
The effect of miR-122 to augment the replication and translation of HCV is 
unusual.  This is the only case in which a miRNA binds to RNA genome and promotes 
RNA polymerization.  The only similar function might be in the amplification of siRNAs 
in plants and in worms and it has always intrigued me that small RNAs might have 
interesting influences on RNA directed RNA polymerases.   
Stimulation of translation of an mRNA following miRNA binding is rare but not 
unique to HCV.  MiR-10a has a similar function in the promotion of translation by 
binding the conserved 5' terminal oligopyrimidine tract (5'TOP) of the ribosomal protein 
(RP) mRNAs (Orom, et al., 2008).  Under conditions of amino acid starvation, miR-10a 
functions to repress translation of RP mRNAs, however, following anisomycin treatment 
or overexpression of RAS, miR-10a switches to a role into translational induction. 5’TOP 
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motif comprises the core of the translational cis-regulatory element of the mRNAs 
involved in translation and ribosome biogenesis and confers sensitivity to mitogens and 
nutrients in eukaryotes (Meyuhas, et al., 2000). Therefore, the translation control of TOP 
mRNAs is important for the biosynthesis of the translational machinery and cell growth. 
However, it is interesting to note that miR-10a was found to be capable of both 
translation repression via interaction with binding sites in the 3’UTR and translation 
enhancement through associating with 5’UTR of different groups of mRNAs. Similarly, 
miR-122 can also induce translational repression of an mRNA construct bearing miR-122 
binding sites in its 3’UTR (Jopling et al., 2008). Therefore, the same miRNA may behave 
differently depending on the binding site positions and also cellular growth conditions.  
MiR-122 functions as a key regulator of lipid and cholesterol biosynthesis in the 
liver. Sequestration of endogenous miR-122 by locked-nucleic-acid-modified 
oligonucleotide (LNA-antimiR) resulted in reduced mevalonate pathway activity, 
suppression of  liver and plasma cholesterol levels, as well as reduced fat accumulation in 
the livers of mice and non-human primates (Elmen, et al., 2008). Furthermore, evidence 
indicates that miR-122 is essential for maintaining liver cell identity and serves as a 
diagnostic and prognostic marker; its inhibition could increase the risk of developing 
hepatocellular carcinoma (Bai, et al., 2009). Since cholesterol and lipoproteins are 
integral components of virion structure, and important for viral circulation and lifecycle 
(Andre, et al., 2002; Kapadia, et al., 2007), it is suggested that miR-122 could also be 
indirectly linked to regulate viral entry, assembly or egress of infectious virus. It will 
become an invaluable target to expand our knowledge in the pathophysiology of diverse 
liver diseases. 
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 Lanford and colleagues recently found that sequestering miR-122 in the liver of 
chimpanzees by intravenous injection of LNA SPC3649, resulted in a dramatic reduction 
in serum HCV without yielding emergent viral resistance and side effects to host liver 
functions (Lanford, et al., 2010). Their findings pointed the way to study alternative 
cellular targets for anti-HCV therapies; in particular, targeting miR-122 may become a 
potential novel antiviral approach to restrain HCV infection. A better understanding of 
the mechanisms responsible for miR-122 modulating HCV infection and its dependence 
on the critical host factors will greatly contribute to the development of innovative and 
more effective antiviral therapeutics. Motivated by these scenarios, we started our 
investigations with two essential miRISC proteins responsible for miRNA biogenesis in 
the miRNA pathway, Dicer and TRBP. 
 
      1.7 Human Dicer 
Dicer is a cytoplasmic RNase III family protein found in most eukaryotes.  
Mammalian genomes encode only one Dicer protein.  Human Dicer is a large (~220 kDa) 
multi-domain protein with an N-terminal DExH/DEAH box RNA helicase domain, a 
domain of unknown function (DUF283), a Piwi Argonaute Zwille (PAZ) domain, two 
RNaseIII domains (RIIIa and RIIIb), and a C-terminal double-stranded RNA binding 
domain (dsRBD) (Murphy, et al., 2008; Murchison, et al., 2004). The DExH/DEAHbox 
family of ATP-dependent RNA helicase plays a central and essential role in the miRNA 
machinery, including unwinding miRNA precursors. In addition, the Dicer helicase has 
been suggested to act as an “RNPase”, remodeling the processing steps and the 
interaction between miRNAs and other RNAs entering the miRNA pathway and 
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ribonucleoprotein complexes (RNPs) (Schwer, et al., 2001).  So far, the dsRNase activity 
of either recombinant or endogenous human Dicer exhibits no ATP requirement in vitro 
(Zhang, et al., 2002; Provost, et al., 2002); however, this cannot preclude the existence of 
a distinct ATP-dependent catalytic activity mediated by additional factors in the RNAi 
pathway in vivo.  
Dicer recognizes its pre-miRNA substrates in a polar manner with the RNase IIIa 
domain always processing the protruding 3’-OH-bearing RNA strand, and RNase IIIb 
cleaving the opposite 5’-phosphate-containing strand to generate products with 2 nt 3’ 
overhangs (Zhang, et al., 2004). The 2 nt 3’ overhangs are recognized by the PAZ 
domain. PAZ is a highly conserved domain unique to Dicer and Ago proteins. PAZ in 
Dicer has a particular specificity for miRNA/siRNA with 2 nt 3’ overhang structure 
characteristic of RNase III processing, which suggests that Dicer plays an essential role in 
the recognition and selection of pre-miRNA substrates pre-processed by Drosha 
(Murchison, et al., 2004). Dicer is also involved in loading of miRNAs into the RISC 
complex (Chendrimada, et al., 2005; Doi, et al., 2003) and interestingly, in vitro assembly 
of RISC with pre-miRNA was more efficient than with pre-cleaved miRNA duplex, 
indicating that the miRNA/siRNA biogenesis and RISC loading  steps are tightly coupled 
(Gregory, et al., 2005). The mechanism of dsRNA processing and RISC loading by 
human Dicer has been most extensively investigated; however, possible functions of 
Dicer in the effector steps of posttranscriptional regulation are not fully elucidated.  
Dicer activities in many cases are crucial to the cell.  General knockout of Dicer1 
in the mouse causes morphologic abnormalities and stunted growth in embryonic day (E) 
7.5 embryos and embryonic lethality by day 11.5 (Bernstein, et al., 2003). In order to 
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study the effects of Dicer knock-out in particular tissues, conditional knockout of Dicer 
has been explored by developing Dicer alleles with the second RNAse III domain flanked 
by loxP sites (Dicer fl/fl) to facilitate conditional knockdown (cKO) of Dicerfl/fl via 
tissue-specific recombination by Cre recombinase  (Bernstein, et al., 2003). Disrupting 
Dicer was found to compromise formation of miRNAs and was found to influence 
vertebrate development (Bernstein, et al., 2003; Giraldez, et al., 200), alter cell 
morphology (Harris, et al., 2006), increase apoptosis (Asada, et al., 2008), decrease cell 
proliferation (Murchison, et al., 2005), and inhibit differentiation (Kanellopoulou, et al., 
2005). Other processes controlled by Dicer related miRNA activities which were 
disrupted in conditional Dicer knockouts were the decreased formation of 
heterochromatic structures (Fukagawa, et al., 2004) and reduced centromeric silencing 
(White, et al., 2004). Dicer may play an important role in the development of cancer 
through epigenetic regulation of as yet unknown genes.  In most cases, knockout of Dicer 
reduced cell proliferation and up regulated apoptosis, for example, knockdown of Dicer 
was shown to inhibit human breast carcinoma cell growth via G1 arrest and up-regulation 
of cell cycle-dependent kinase inhibitor (CKI) p21 and p27 (Bu, et al., 2009). However, a 
few exceptions exit.  Inhibition of Dicer was reported to enhance tumor proliferation  and 
invasion via activated p-Akt pathway and enhanced expression of the cell cycle 
associating molecules, cyclin A and PCNA, as well as MMP-2 and MMP-9 (Han, et al., 
2010). In addition, conditional depletion of Dicer from murine Schwann Cells was found 
to increase their proliferation while blocking myelination (Bremer, et al., 2010; Pereira, 
et al., 2010). Also, dicer knockdown in Huh 7.5 cells caused no significant effect on cell 
proliferation (Randall, et al., 2007).  In general, it appears that Dicer is essential for 
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efficient cell growth, but in certain cases Dicer knockdown or knockout can have a 
neutral or even positive effect on cell growth.   
 
      1.8 Human TRBP 
TRBP1 and TRBP2 are two isoforms transcribed by the human tarbp2 gene.  The 
two mRNAs are initiated from adjacent promoters that transcript alternative first exons, 
which are spliced into common downstream exons. As a consequence, in comparison to 
TRBP1, TRBP2 has 21 additional amino acids at its N-terminus (Bannwarth, et al., 2001). 
TRBP2 has two double-stranded RNA binding domains, the second one containing a KR-
helix motif that mediates dsRNA binding (Daviet, et al., 2000). A third basic domain, 
Medipal domain in the C-terminal end of TRBP mediates protein-protein interactions 
(Laraki, et al., 2008).  
The TRBPs were identified through their ability to bind the HIV-1 transactivating 
response (TAR) RNA (Daher, et al., 2001) and stimulate of the expression of the HIV 
long terminal repeat (LTR) in human and murine cells (Gatignol, et al., 1991). 
In mammalian cells, TRBP (~45 KDa) was found to be a protein binding partner 
of Dicer (Rossi, et al., 2005) through the C-terminal binding site of TRBP (Daniels, et al., 
2009). TRBP is required for RNAi function mediated by both siRNAs and miRNAs. 
Knocking down either Dicer or TRBP resulted in the destabilization of both proteins and 
a substantial decrease in the accumulation of mature miRNAs (Chendrimada, et al., 
2005). TRBP is proposed to act as a biosensor in strand selectivity that ensures proper 
loading of the 3’ end of the guide strand onto the Ago2 (Castanotto, et al., 2007).  In the 
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absence of TRBP, the Ago2-Dicer complex disassociates entirely under dilution 
conditions used for EM grid preparation. This observation suggests that TRBP increases 
the affinity of Ago2 for Dicer, and that TRBP facilitates  the association of Dicer and 
Ago2 in the process of miRNA loading into RISC (Wang, et al., 2009; Chendrimada, et 
al., 2005).  Furthermore, Dicer, TRBP and Ago2 are necessary and sufficient for in  vitro 
reconstitution of the RNAi activity (MacRae, et al., 2008) 
TRBP was found to increase HIV protein expression and replication by directly 
binding to the interferon-induced dsRNA-activated protein kinase PKR through its 
dsRBDs and blocking the inhibitory effects of PKR on HIV (Ong, et al., 2005).  TRBP 
has a direct effect on stimulating the translation of TAR containing structured RNA in 
PKR–/– MEF, which is independent of its ability to inhibit the translational block imposed 
by PKR (Dorin, et al., 2003). 
TRBP functions as a translational regulator during mouse spermatogenesis and 
has a physiological role in growth control during development (Zhong, et al., 1999). 
Overexpression of TRBP in NIH3T3 cells caused enhanced cell growth and transformed 
phenotypes, such as anchorage-independent cell growth and tumor development in mouse 
xenografts  (Benkirane, et al., 1997). A tumor suppressor named merlin was shown to 
efficiently inhibit these oncogenic activities of TRBP (Lee, et al., 2004).  
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      1.9 Hypothesis and Objectives 
Previous research on identifying cellular cofactors involved in the host miRNA 
pathways that affect HCV infection and replication inspired my thesis work. Randall et al. 
(2007) demonstrated that siRNA-mediated knockdown of Drosha, DGCR8, Dicer, or 
each of the four Argonaute proteins significantly diminished the accumulation of viral 
RNA and infectious virus production in HCV-infected cells. In addition, work in our 
laboratory on the effects of Ago knock-down on HCV supported Randall’s work. 
However, the mechanism by which the miRNA pathway is involved in HCV infection 
remains unsolved. Randall et al. hypothesized that the inhibition of HCV by siRNA 
targeting Dicer may be due to Dicer’s function in miR-122 biogenesis; however, they did 
not further investigate whether endogenous miR-122 levels were decreased by Dicer 
knockdown.  
In this study, we aimed to provide evidence of the significance of RISC proteins 
in modulating HCV infection and deepen our understanding of the mechanism. Our 
laboratory supports a model in which the mechanism of HCV replication augmented by 
miR-122 involves the association of miR-122 with a protein complex, similar to the RISC 
complex. Since Dicer and TRBP are two essential RISC proteins that may play a role in 
downstream RISC function through the association with Agonaute proteins, we 
considered the possibility that Dicer and TRBP are required for both miR-122 biogenesis 
and miR-122 mediated HCV replication, most likely through functions in miRNA 
loading into Ago2 and RISC.  
My research was motivated by two hypotheses: 
I. Knock-down of Dicer and TRBP decrease HCV replication and translation. 
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II. Dicer and TRBP are not only responsible for miR-122 biogenesis, but also 
modulate HCV replication through their roles in RISC assembly step of RNA 
interference.  
                  To test these hypotheses, I established the following objectives: 
I. Design siRNAs to knock down Dicer and TRBP and observe the effects on 
full length J6/JFH-1 HCV replication and translation in Huh7.5 cells.   
II. Determine specific roles of Dicer and TRBP in HCV replication by analyzing 
endogenous miR-122 changes following Dicer and TRBP knockdown.  
III. Design an HCV replication assay independent of wild type miR-122 by 
introducing mutations to seed sequence binding sites of 5’UTR, and 
characterize whether Dicer and TRBP have direct roles in mutant HCV 
replication complemented by miR-122 with complementary mutations, such 
as their roles in RISC assembly step of the RNAi machinery.  
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2.0 MATERIALS AND METHODS 
2.1 Viruses:   
         FL-J6/JFH-1-RLuc-WT is a full length-genotype 2a sequence that is capable of 
replication and virus particle production in cell culture. It is a chimeric virus RNA 
containing a 5’ untranslated region (5’ UTR) from the genotype 2a JFH-1 isolate, 
structural proteins core through NS2 from the genotype 2a J6 isolate and non-structural 
proteins through 3’UTR from the genotype 2a JFH-1 isolate. It also contains an inserted 
Renilla Luciferase (RLuc) reporter gene between p7 and NS2. RLuc is cleaved from the 
polyprotein  at p7  downstream and foot-and-mouth disease virus (FMDV) 2A  peptide 
cleavage site upstream of NS2 (Jones, et al., 2007) (Figure 2-1A). 
          FL-J6/JFH-1-RLuc-GNN: is a non-replicative mutant of HCV J6/JFH-1. It is 
identical to the replicative wild-type genome, but contains a point mutation which 
abolishes RNA polymerase activity of NS5B (Tomoko D. et al., 2004) (Figure 2-1B). 
           FL-J6/JFH-1-RLuc-m3-4: nucleotides at positions 3 and 4 of each miR-122 
binding site were mutated to their complements (i.e., U26C to A27G and U41C to A42G), 
such that the mutant sites are not predicted to bind wild-type miR-122 (wt miR-122). 
Instead, they should bind to mutant miR-122p3-4, which was designed to restore base 
pairing to the viral RNA-miRNA pair (Jopling. et al., 2008) (Figure 2-1C). 
 
Figure 2-1: Schematic constructions of chimeric full length HCV genome and 
derivates: (A). FL-J6/JFH-1-RLuc-WT (B). FL-J6/JFH-1-RLuc-GNN (C).   FL-J6/JFH-
1-RLuc-m3-4 
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2.2 Cell Culture: 
         Huh 7.5 cells are a subline derived from Huh7 human hepatoma cells and are highly 
permissive for HCV replication (Blight KJ, et al., 2002). Huh7.5 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Burlington, ON Canada) 
supplemented with 10% fetal bovine serum (FBS, Multicell, Wisent Inc., St. Bruno, QC, 
Canada), 1% Penicillin Streptomycin (10,000 units/ml Penicillin, 10,000 µg/ml 
Streptomycin) (Invitrogen, Burlington, ON Canada) and 1% nonessential amino acids 
(100x, Multicell, Wisent Inc.; St. Bruno, QC, Canada) at 37ºC in the presence of 5% CO2. 
 
2.3 siRNAs/microRNAs 
          Table 2-1. The sequences of siRNAs/miRNAs used in this study. 
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          Mature miRNA duplexes were annealed with equimolar amounts of either wild 
type or p3-4 forms of miR-122 with a common complementary miRNA strand miR-122*. 
 
      2.4. In Vitro Transcription of HCV RNA  
             2.4.1 Preparation of viral RNA from full length HCV plasmid constructs  
5 µg of plasmid encoding full length chimeric HCV genome was digested with 
2µl XbaI (New England Biolabs, ON Canada) combined with 1 x BSA and 1 x NEB 4 
(New England Biolabs, ON Canada). The reaction mixture was brought to the final 
volume of 45 µl by ddH2O and incubated at 37° C for 1 hour. Addition of another 1.5 µl 
of XbaI for another hour gave more efficient digestion. 5’ overhangs of linearized DNA 
were removed by adding 1 µl of mung bean nuclease (New England Biolabs, ON Canada) 
at 37° C for 1 hour. 
 
             2.4.2 Phenol and Chloroform Extraction of Linearized DNA 
Linearized DNA was extracted by using 25 µl each of tris-saturated phenol 
(Invitrogen, Burlington, ON Canada) and chloroform (Sigma; Oakville, ON, Canada) to 
make an equal volume to the sample. The DNA was precipitated by adding 5 µl of 3 M 
sodium acetate combined with 100 µl of 100% ethanol, and chilled at -20° C for a 
minimum of 2 h. DNA pellets were centrifuged at 14,000 x rpm for 10 min and 
resuspended in 10 µl ddH2O.  
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            2.4.3 In Vitro Transcription of HCV RNA  
In vitro transcription of HCV RNA was performed using MEGAscript® T7 Kit 
(Ambion; Streetsville, ON, Canada) following the supplied protocol.  
 
             Table 2-2. MEGAscript®T7 In vitro Transcription Reaction Assembly mix: 
  
 
 
   
 
 
 
    
      
 
The transcription reaction was incubated overnight at 37° C in an air incubator. 
On the following day, the reaction was treated with 1 µl of TURBO DNAse at 37° C for 
20 min to remove the template DNA and the reaction was then terminated by adding 115 
µl Nuclease free Water and 15 µl Ammonium Acetate Stop Solution. 
 
            2.4.4 Phenol and Chloroform Extraction and RNA Precipitation 
HCV RNA was extracted with equal volumes of phenol/chloroform (75 µl), and 
then extracted once with an additional 150 µl of chloroform. The RNA containing 
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aqueous phase was collected and the RNA precipitated by adding 150 µl isopropanol and 
chilling for at least 2 hours at -20° C. RNA pellets were centrifuged and resuspended in 
50 µl DEPC-H2O, and RNA concentration was determined by using a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Purified 
total RNA samples were stored at -80º C.  
2.5  Transient HCV Replication Assay 
Huh7.5 cells were washed with ice-cold Dulbecco’s DPBS (Multicell, Wisent Inc.; 
St. Bruno, QC, Canada), trypsinized by 2 µl trypsin-EDTA (0.05 % trypsin, 0.53 mM 
EDTA) (Multicell, Wisent Inc.; St. Bruno, QC, Canada), and resuspended in complete 
growth medium. Cells were pelleted by centrifugation (1000 x rpm for 5 min at 4°C), 
then washed twice with ice-cold DPBS, and resuspended in ice-cold DPBS at 1 x 107 
cells/ml. 400 µl cell suspensions were mixed with 60 nM siRNAs (control siRNA, 
siDicer and siTRBP) and placed into 4 mm gap electroporation cuvettes (VWR, 
Edmonton, AB, Canada). Electroporation was performed by using Gene Pulser X cell™ 
(Bio-RAD, Mississauga, ON, Canada)  with settings: 270 v, 950 µF, ∞ Ω, 4mm cuvette. 
Following the electroporation, cells were immediately resuspended in 8 ml of complete 
growth medium. Approximate 6 x 106 electroporated cells were plated into 150 x 15 mm 
tissue culture dishes (Sarstedt, Inc. Newton NC, USA  ) and grown at 37° C for 3 days 
prior to the second electroporation. The second electroporation was performed on day 3 
post electroporation (p.e.) using the same procedure as described above, but cells were 
co-electroporated with 5 μg of  FL-J6/JFH-1-RLuc-WT (Figure 2-1)  or FL-J6/JFH-1-
RLuc-GNN RNA (Figure 2-2) transcripts and 60 nM of the same siRNA used in the first 
electroporation. Cells were resuspended in 8 mL of media and plated as required for 
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subsequent assays, and incubated at 37° C prior to harvest. 1.2 x 105 cells were plated for 
luciferase assay and cell lysates were collected at 1 h and 72 h post second 
electroporation (p.s.e.). 9.6 x 106 cells were plated for RNA analysis at 72 h p.s.e. 4.8 x 
103 cells were plated and cell viability was measured by WST-1 Assay at 72 h p.s.e. 2.4 x 
105 cells were plated and harvested at 72 h p.s.e for protein analysis.  
 
2.6 HCV Translation Assay 
Similar to the method used in the transient replication assay, Cells were prepared 
and electroporated with siRNAs to knockdown the desired genes (control siRNA, siDicer 
and siTRBP).  Three days later the cells were electroporated a second time with 5 μg FL-
J6/JFH-1-RLuc-GNN RNA (Figure 2-2), and 1µg capped Firefly Luciferase (FLuc) 
reporter mRNAs as endogenous control. 1.2 x 105 cells were plated for luciferase assay 
and cell lysates were collected at 3.5 h, 4 h, and 4.5 h p.s.e. 9.6 x 106 cells were plated for 
qRT-PCR analysis and collected at 4 h p.s.e. 4.8 x 103 cells were plated and cell viability 
was measured by WST-1 Assay at 24 h p.s.e.  
 
2.7 HCV Transient Replication Assay for miR-122p3-4 Rescue 
Cells were prepared for electroporation as described in section 2.5 and 
electroporated with 5 μg FL-J6/JFH-1-RLuc-m3-4 (Figure 2-3), or 5 μg FL-J6/JFH-1-
RLuc-GNN RNAs, together with 60 nM siRNAs (control siRNA, siDicer and siTRBP) 
and 40 nM miRNAs (micontrol or miR-122 duplex)  were co-electroporated into huh 7.5 
cells.  1.2 x 105 cells were plated for luciferase assay and cell lysates were collected at 1 h 
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and 72 h post electroporation (p.e.). 4.8 x 103 cells were plated and cell viability was 
measured by WST-1 Assay at 72 h p.e.  
 
2.8  WST-1 Assay 
To test cell viability, 4.8 x 103 HCV-infected huh 7.5 cells were seeded into 96-
well plates with 100 µl culture medium. At 72h p.s.e., the culture medium was changed 
with 110 µl/well fresh medium containing 10µl WST-1 (Roche Diagnostics, Laval, 
Quebec, Canada) and cells were incubated for another 4 h at 37 ºC, 5% CO2. A triplicate 
of blank wells with the same volume of culture medium and WST-1 were set as a 
background control. Standard curves were generated by 2 - fold dilutions of 9.6 x 103 
unelectroporated cells. The absorbance of the samples against a background control as 
blank was measured using a microplate (ELISA) reader Spectramax 340PC (Molecular 
Devices) with the wavelengths 450 / 650 nm. Cell numbers directly correlating with 
absorbance were calculated from the standard curve. 
 
2.9  Western Blotting 
Dicer and TRBP protein expression levels were analyzed by SDS-PAGE. 2.4 x 
105 cells were plated and total Cell lysates were collected at 72h p.s.e. in 1 x SDS lysis 
buffer (2% SDS, 62.5 mM Tris-HCl, pH 6.7, 30% glycerol, 0.002% bromophenol blue, 2% 
β-mercaptoethanol) and 1 M Dithiothreitol (Sigma, Oakville, ON, Canada) before being 
denatured at 96º C. Whole cell extracts were electrophoresed on an SDS-PAGE gel 
consisting of a 4% stacking gel and 12% resolving gel for TRBP and 6% for Dicer (due 
to different molecular weights of proteins). For electrophoresis, 2 µl of Bench MarkTM 
prestained protein ladder or Novex® sharp pre-stained protein standards (Invitrogen, 
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Burlington, ON Canada) and 25 µl of each sample were loaded on the SDS-PAGE gel 
and run in 1 x SDS running buffer (2.5 mM Tris-HCl, 192 mM glycine and 0.1% SDS, 
pH 8.3) at 150 V for 1 h (until loading dye ran off the gel). The separated proteins in the 
SDS-PAGE gel were transferred to a Hybond C+ nitrocellulose membrane (Amersham 
Pharmacia Biotech, Québec, Canada) for 90 min at 400 mA in 1 x transfer buffer (28.8 g 
glycine, 6.04 g Tris base, 200 ml menthol, 1.6 L ddH2O). The membranes were blocked 
for 1 h at Room Temperature (RT) with 3% BSA in 1 x D-PBS, and incubated overnight 
at 4º C with primary Dicer 14601 monoclonal antibody (Abcam Cambridge, MA, USA) 
diluted 1/100, or TRBP 42018 polyclonal antibody (Abcam Cambridge, MA, USA) 
diluted 1/500, together with β actin 6276 monoclonal antibody (Abcam Cambridge, MA, 
USA) at a 1/1000 dilution. The next day, the membranes were washed in PBS-A 3 times 
and treated with secondary Odyssey goat anti-Rabbit IRDye@680 for TRBP1, Odyssey 
Goat anti-Mouse IRDye@880 (Li-Cor Biotech, Lincoln, NE, USA) for Dicer and β-actin 
diluted 1/10,000 in 3 % BSA. The membranes were then incubated for 1 h at RT and 
washed three times in 1 x D-PBS in a dark environment. Protein bands were visualized 
and quantified by Odyssey® Infrared Imaging System (Li-Cor Biotech, Lincoln, NE, USA) 
according to the manufacturer's protocol. 
 
    2.10 Luciferase Assay: 
For HCV transient replication assay, 1.2 x 105 cells were plated. Infected cells 
lysates were collected at 1 h and 72 h p.s.e. and washed twice with 1 x D-PBS and lysed 
by adding 100 µl 1 x Renilla luciferase lysis buffer (Promega Biosciences; Nepean, ON, 
Canada) and rocked gently at room temperature (RT) for 15 min. Renilla luciferase 
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activity was measured using the GLOMAX luminometer (Promega Biosciences; Nepean, 
ON, Canada) by mixing 10 µl cell lysates with 50 µl 1 x Renilla luciferase assay buffer 
(Promega Biosciences; Nepean, ON, Canada). 
For HCV transient translation assay, washed cells were lysed in 100µl 1 x passive 
lysis buffer (Promega Biosciences; Nepean, ON, Canada). FLuc activity was determined 
by mixing 10 µl cell lysates with 50 µl Dual luciferase assay buffer (Promega 
Biosciences; Nepean, ON, Canada), and measuring luminescence on the GLOMAX 
luminometer, and then adding 50 µl Stop & Glow® Reagent (Promega Biosciences; 
Nepean, ON, Canada) to quench FLuc activity and activate Renilla Luciferase for a 
second measurement on the GLOMAX luminometer.  
 
      2.11 RNA Analysis 
               2.11.1 Total RNA Isolation 
9.6 x 106 electroporated cells were seeded for RNA analysis. For quantitating 
viral RNA, total RNA was extracted from cells with 1 ml Trizol reagent (Invitrogen, 
Burlington, ON Canada) at 72h p.s.e. according to the manufacture’s protocol. Cell 
lysates were incubated for 5 min at RT to permit the complete dissociation of 
nucleoprotein complexes. 0.2 ml of chloroform per 1 ml of Trizol was added. The 
samples were vigorously shaken by hand for 15 s and incubated at RT for 2-3 min. The 
samples were then centrifuged at 12,000 x g for 15 min at 4° C. After centrifugation, the 
colorless upper aqueous phase was extracted and transferred to fresh tubes. RNA in the 
aqueous phase was precipitated by mixing with 0.5 ml isopropyl alcohol (isopropanol) 
per 1 ml of TRIZOL reagent used for the initial homogenization. The RNA samples were 
vigorously shaken by hand for 15 s and incubated at RT for 10 min, following by 
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centrifuging at 12,000 x g for 15 min at 4° C. Following centrifugation, the supernatant 
was removed and RNA pellet was washed with l ml 75% ethanol and centrifuged at 7,500 
x g for 5 min at 4° C.  At the end of the procedure, the RNA pellet was briefly air-dried, 
resuspended in an approporiate volume of DEPC-H2O and quantified using a NanoDrop 
ND-1000 Spectrophotometer. Purified total RNA samples were stored at -80º C for 
further analysis.  
 
           2.11.2 Quantitative Reverse Transcriptase PCR (qRT-PCR).  
                       2. 11.2.1 TaqMan Gene Expression Assay 
First-strand cDNA synthesis was performed using iScriptTM Select cDNA 
Synthesis Kit (Bio-RAD, Mississauga, ON, Canada). A volume of 1 μg total RNA was 
combined with 4 μl of 5 × iScript select reaction mix, 2 μl of random primer, 1 μl of 
iScript reverse transcriptase, and RNase-free water to a final volume of 20 μl. For 
random-primed cDNA reaction, the reaction mixture was incubated at 25° C for 5 min, 
42° C for 30 min, and the reverse transcriptase was heat-inactivated at 85° C for 5 min. 
The cDNA products were stored at -20° C for further analysis.  
Relative amounts of Dicer or TRBP to human GAPDH mRNAs were quantified 
by using TaqMan Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA) 
according to manufacturer’s protocol. Gene specific fluorescent probes for Dicer 
(Hs00229023_ml 20 x mix), TRBP1 (Hs00366328_ml 20 x mix), and GAPDH (FAM-
MGB 4352934-0803022) were commercially purchased from Applied Biosystems.  
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             Table 2-3. TaqMan Gene Expression Assay reaction mix: 
 
 
The qRT-PCR step was performed in 96-well PCR plates in triplicate by using 
CFX 96 TM system (Bio-RAD, Mississauga, ON, Canada).  
 
           Table 2-4. qPCR thermal cycling conditions for TaqMan Gene Expression Assay: 
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            2.11.2.2 Eva Green Gene Expression Assay  
For studying HCV transient translation, relative RNA amounts of HCV to firefly 
luciferase reporter mRNA were quantified by Eva Green gene expression assay. First-
strand cDNA synthesis was performed using iScriptTM Select cDNA Synthesis Kit (Bio-
RAD, Mississauga, ON, Canada) with JFH-1 FL/SGR primer: 5’ 
CGGTGAACCAACTGGATAAG 3’ to reverse transcribe the whole HCV genome from 
3’UTR, and firefly luciferase primer: 5’  TTTGGACTTTCCGCCCTTCTTG  3’.  
 
          Table 2-5. iScriptTM Select cDNA RT reaction master mix for specific primers:  
 
    
     
 
 
 
 
 
 
 
 
           For gene-specific primers, reverse transcription was incubated at 42° C for 60 min, 
and the reverse transcriptase was heat-inactivated at 85° C for 5 min. The cDNA products 
were stored at -20° C for further analysis.  
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Relative amounts of Renilla luciferase RNA (representing HCV RNA amounts) to 
Firefly luciferase RNA (controlling for transfection efficiency) were quantified by real 
time PCR using Sso FastTM EvaGreen Supermix (Bio-RAD, Mississauga, ON, Canada) 
according to manufacturer’s protocol. The gene specific primers used were 5’ 
TCGCCAGTCAAGTAACAAC 3’ and 5’ ACTTCGTCCACAAACACAA 3’ to amplify 
firefly luciferase cDNA and 5’ AACGCGGCCTCTTCTTATTT 3’ and 5’ 
GTCTGGTATAATACACCGCG 3’ for Renilla Luciferase found in HCV replicion 
genome (Jopling. et al., 2008). QRT-PCR was carried out using CFX 96 TM system (Bio-
RAD, Mississauga, ON, Canada).   
 
         Table 2-6. EvaGreen Gene Expression Assay reaction mix: 
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           Table 2-7. Optimized qRT-PCR thermal cycling conditions for EvaGreen Gene 
Expression Assay: 
 
 
 
 
 
   
        
Relative quantification was analyzed with the Bio-Rad CFX manager software 
(Bio-RAD, Mississauga, ON, Canada) using ΔΔCt method. The relative transcript level 
of each treatment was determined by a formula as follow:  
                 Ratio= (Etarget)ΔCt target (Control-treated) /(Ereference)ΔCt reference (Control-treated)  
E represents the efficiency for the primers; ΔCt represents the difference in the Ct values, 
which is the point at which the fluorescence crosses the threshold. Human GAPDH was 
used in this study as the reference gene (Pfaffl, et.al. 2001). 
 
               2.11.2.3 miR-122 qRT-PCR. 
For qRT-PCR analysis of endogenous miR-122 amounts following Dicer and 
TRBP knock down, 1 µg of total RNA was reversed transcribed in vitro to cDNA by 
miR-122 (lot: 0810096-B) and small nuclear RNA U6 (U6 snRNA) (lot: 090290-C) 
specific RT primers provided by TaqMan® MicroRNA Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA, USA), according to manufacturer’s instructions.  
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                Table 2-8. TaqMan® MicroRNA Reverse Transcription master mix: 
 
 
 
    
 
 
 
          
            
 
         The reverse transcription was incubated at 16° C for 30 min and 42° C for 30 min, 
and the reverse transcriptase was heat-inactivated at 85° C for 5 min. The cDNA products 
were stored at -20° C for further analysis.  
          QRT-PCR reaction was set up and performed according to protocols described in 
TaqMan Gene Expression Assay (9.2.1) with specific probes for miR-122 (lot: 0810096-
B) and U6 snRNA (lot: 090290-C). 
 
          2.11.3 Total RNA Northern Blot: 
8 µg of total RNA was denatured by using 2.7 µl deionized glyoxal (8.8 M; Sigma, 
Oakville, ON, Canada), 8.5 µl DMSO and 1.6 µl 0.1 M (pH 7.0) Sodium Phosphate 
buffer at 55º C for 1 h. Following denaturation the RNA samples were separated in 0.8% 
denaturing agarose gel (0.1 M NaH2PO4, 0.1 M NaHPO4, 0.05 M EDTA, (0.1% DEPC 
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treated) H2O, pH 7.0) and then transferred to Hybond N+ membrane (Amersham 
Pharmacia Biotech, Québec, Canada). The membrane was hybridized overnight in 1 x 
hybridization solution (5 x SSC, 5 x Denhardts solution, 1% SDS, 0.1% DEPC H2O), 100 
µg/ml denatured salmon sperm DNA (Sigma,  Oakville, ON, Canada) with random-
primed 32P-labeled DNA probes complementary to 2940 kb fragment cut by EcoR V and 
BamH I from pSGR-J6/JFH-1-RLuc and to 1.3 kb fragment cut by PST1 from pUC8 
hGAPDH. Following hybridization, the membrane was washed twice in wash buffer 1 
(1x SSC, 1% [w/v] SDS) for 45 min and twice in wash buffer 2 (0.1 x SSC, 0.1% [w/v] 
SDS) for 45 min at 65°C and then exposed to a phosphorimaging screen (Bio-RAD, 
Mississauga, ON, Canada) overnight. Blots were quantified with Molecular Imager® 
(Bio-RAD, Mississauga, ON, Canada). 
 
2.12  Statistical Analysis  
All data are shown as mean ± SD of three independent experiments. Results were 
analyzed for statistical differences using Student’s t test. A p value of ≤ 0.05 was 
considered to be statistically significant.  
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3.0 RESULTS 
3.1  siRNA knock-down of Dicer and TRBP: mRNA, protein levels,  cell viability 
To further test our siRNA efficacies, total cellular RNA was extracted from 
Huh7.5 cell lysates at 72 h p.s.e. and quantitated by qRT-PCR for the amounts of Dicer 
and TRBP mRNAs. Human GAPDH serves as an internal control. The data in Figure 3-
1A show that both Dicer and TRBP mRNAs in Huh7.5 cells were strongly reduced by 
respective siRNA treatments, compared to the control siRNA. 
            To evaluate the activities of the synthetic siRNAs in decreasing the expression of 
Dicer and TRBP proteins, infected Huh7.5 cell extracts were separated on SDS-PAGE 
and amounts of Dicer and TRBP proteins were analyzed by Western Blot at 72 h p.s.e, 
and normalized to human β-actin. SiDicer and siTRBP induced almost complete 
inhibition of protein expression, compared to control siRNA (Figure 3-1B). Since 
knocking down either Dicer or TRBP was assumed to destabilize the association of both 
proteins and a substantial reduction in the accumulation of mature miRNAs 
(Chendrimada, et al., 2005), we suspected that knock-down of Dicer and TRBP would 
block the miR-122 biogenesis pathway and further interrupt HCV replication regulated 
by miR-122.  
Since Dicer and TRBP are two essential proteins responsible for miRNA 
maturation in mammalian cells, their knock-down could induce a global down-regulation 
of miRNA and possible side effects including alterations of pivotal functions in cellular 
physiology, such as cell proliferation and apoptosis. To determine whether transient 
reductions of Dicer and TRBP induces cytotoxic effects in the context of HCV infection, 
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we measured the metabolic activities of viable infected cells 72 h following Dicer and 
TRBP knock-down by using WST-1 cell proliferation assay. WST-1 is a tetrazolium salt 
which can be cleaved by mitochondrial dehydrogenases, upon cleavage it releases a 
florescent dye whose wave length can be conveniently measured on an ELISA plate 
reader.  The assay works on the premise that viable cell’s mitochondrial dehydrogenases 
have equivalent activity. Therefore equivalent cell numbers will give a similar 
absorbance.  For the purpose of our experiments a standard curve was made and the cell 
numbers of our samples are extrapolated off the curve. The results showed that knock-
down of Dicer and TRBP had no appreciable effects on cell viability in our transient 
HCV replication assay, compared with cells treated with control siRNA (Figure 3-1C).  
Our observations agreed with Randall’s work that there is no correlation between the 
effect of disrupting Dicer in the context of HCV infection and cell viability, suggesting 
that reduced HCV replication do not result from changes in cellular physiology (Randall, 
et al., 2007). In addition, our observation was indirectly supported by the finding that 
down regulation of Dicer and TRBP in transient HIV infection of HeLa cells did not 
affect cell viability (Christensen, et al., 2007).  
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Figure 3-1: Cellular Dicer and TRBP mRNA amounts, protein expression and cell 
viability following siRNA knockdown. 
(A): The effects of siRNAs on target gene expression were assessed by qRT-PCR at 72 h p.s.e. 
Human GAPDH was used as an endogenous control. Values are expressed as fold of mRNA 
inhibition in specific siRNA treated cells versus control siRNA treated cells.    
(B): Total Huh7.5 cell lysates were harvested at 72h post p.s.e. and separated on SDS-PAGE. The 
protein levels of Dicer and TRBP were analyzed by Western Blot with specific antibodies. 
Human Dicer is about 217 kDa and was detected by anti-Dicer 14601 (Abcam) at a 1/100 dilution. 
Human TRBP2 is about 37 kDa and was detected with anti-TRBP42018 (Abcam) at a 1/500 
dilution.  Human β-actin served as an endogenous control. The blots shown above are 
representative results. The blots shown above were generated from one independent experiment. 
(C): The numbers of viable cells were measured by WST-1 assay at 72 h p.s.e. The cell numbers 
of FL J6/JFH-1-RLuc-WT + control siRNA treated sample were set at 1. Values are presented as 
fold of the control sample.  
 
     3.2 siRNA knockdown of Dicer and TRBP attenuated Renilla Luciferase 
expression and HCV RNA abundance.  
It was previously shown that, siRNA-mediated knockdown of Drosha, DGCR8, 
Dicer, or each of the four Argonaute proteins significantly diminished the accumulation 
of viral RNA in HCV-infected cells (Randall, et al., 2007); however, the mechanisms 
explaining why and how these host factors influence HCV replication remained unknown. 
Since Dicer and TRBP are two essential RISC proteins responsible for miRNA 
biogenesis and they associate with Ago2, we considered the possibility that Dicer and 
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TRBP might be required for miR-122 to promote HCV infection. In this study, we 
investigated the specific roles of Dicer and TRBP on HCV replication.  
To analyze the effects of knocking down human Dicer and TRBP on HCV 
replication we measured the amount of Renilla luciferase expression from the reporter 
virus RNA J6/JFH-1-RLuc-WT.  Using this construct the levels of RLuc expression 
correlates with the levels of HCV RNA in the cell.  For these experiments siDicer and 
siTRBP were introduced into Huh7.5 cells 3 days before a subsequent electroporation 
with J6/JFH-1-RLuc-WT HCV genome (Figure 2-1A), or J6/JFH-1-RLuc-GNN (Figure 
2-1B),  and the same amount of siRNA. Cell lysates were harvested at 1 h, or 72 h p.s.e. 
and RLuc activities were measured with Renilla Luciferase Assay reagent (Promega). 
RLuc levels were corrected for electroporation efficiency by normalizing to the RLuc 
expression levels at 1 h p.s.e. (before HCV replication has initiated). The RLuc 
expression from J6/JFH-1-RLuc-GNN RNA was a negative control in our experimental 
design. Knocking down Dicer reduced relative HCV RLuc expression by 42.22%, and 
siTRBP strongly reduced HCV RLuc expression by 70.59%, compared with control 
siRNA treated HCV-infected cells (Figure 3-2A).  
We confirmed the reduction in HCV replication by analyzing HCV RNA 
abundance by using Northern Blot. Total cellular RNA was isolated from the samples in 
the Transient HCV Replication Assay. HCV and human GAPDH bands were probed by 
random-primed 32P-labeled DNA fragment complementary to 2940 kb fragment cut by 
EcoR V and BamH I from pSGR-J6/JFH-1-RLuc and to 1.3 kb fragment restricted with 
PST1 from pUC8 hGAPDH, respectively.  Human GAPDH was quantified to normalize 
signals for equal loading. Northern Blot showed that HCV RNA abundance was reduced 
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by 48.12% by knocking down Dicer (Figure 3-2B) and knocking down TRBP resulted in 
69.55% reduction of HCV RNA accumulation (Figure 3-2C), compared to the J6/JFH-1-
RLuc-WT RNA treated with control siRNA. RNA samples from J6/JFH-1-RLuc-GNN 
treated with control siRNA were below detectable level. Our Dicer knockdown results 
agree with the conclusions of Randall et al. (2007); however, they showed at least 75% 
reduction in the HCV RNA amount. Although, both of our Dicer knockdown efficiencies 
similarly achieved to approx 80% within Huh 7.5 cells, Randall et al. quantified the 
intracellular HCV RNAs at 48 h after siRNA electroporation and HCV infection with a 
multiplicity of 0.5 infectious HCV particles per cell.  Therefore, we believe the different 
results we observed might be due to different experimental designs. 
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Figure 3-2: RLuc expression from HCV RLuc reporter viruses and HCV RNA 
amounts was reduced following siRNA knock-down of Dicer and TRBP. 
(A): Relative RLuc expression of HCV replication assays at 72 h p.s.e. RLuc expression levels 
were reduced following Dicer and TRBP knockdown. RLuc expression levels for each sample are 
presented relative to control siRNA sample. Electroporation efficiency was corrected by using 1 h 
RLuc values. All data are shown as mean ± SD of three independent experiments. Results were 
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analyzed for statistical differences using Student’s t test. A p value of ≤ 0.05 was considered to be 
statistically significant.  *p≤0.05 **p≤0.01 ***p≤0.001 
(B) (C): RNA abundance in HCV replication assays were quantitated by Northern Blot. HCV 
RNA abundance was attenuated by 48.12% by knocking down Dicer (B) and knocking down 
TRBP resulted in 69.55% reduction of HCV RNA accumulation (C). HCV RNA amounts were 
normalized to those of human GAPDH.  The blots shown above are representative results. Values 
were graphed and expressed as fold of FL J6/JFH-1-RLuc-WT + control siRNA treated sample.   
 
 
3.3 Endogenous miR-122 amounts in HCV-infected cells treated with siDicer and 
siTRBP 
Given that Dicer and TRBP are essential proteins for miRNA biogenesis, we next 
inspected endogenous miR-122 amounts in our replication assays to explore whether the 
reduction of HCV replication could be related to diminished miR-122 abundance. We 
isolated total RNA from a HCV transient replication assays following Dicer and TRBP 
knock-down and measured levels of miR-122 at 72 h p.s.e.  To quantify levels of miR-
122 we used a TaqMan MicroRNA Assay Kit (Applied Biosystems) specific for miR-122. 
For quantification of miR-122 we reverse transcribed endogenous mature small RNAs by 
using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and then real 
time quantitative PCR was carried out by using specific primers for miR-122.  Small 
nuclear RNA U6 (U6 snRNA) served as an endogenous control, due to its stable 
expression and relatively constant levels across human tissues and cell lines (Peltier, et 
al., 2008; Jopling, et al., 2006). Unexpectedly, endogenous miR-122 amounts were not 
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significantly downregulated by repressing Dicer, and levels were decreased by 25.7% 
following TRBP knockdown, compared with control siRNA treated sample (Figure 3-4).  
We speculated that we did not see a reduction in miR-122 levels following Dicer 
knockdown due to the high amounts in the cell, since miR-122 accounts for approximate 
70% of the total liver miRNA population and it is expressed at a high level with more 
than 66,000 copies per cell (Jopling, et al., 2005; Girard, et al., 2008). Sekine and co-
workers reported that miR-122 could be almost depleted in hepatocyte-specific Dicer1 
conditional knockout mouse 3 weeks after birth (Sekine, et al., 2009).  And the half-life 
of mature miR-122 half life is estimated to last well beyond 24 h (Gatfield, et al., 2009). 
Therefore, our observation could also be ascribed to the short duration of knock-down in 
our transient HCV replication assay that has almost no effect on high stability mature 
miR-122 levels. However, these data inspired us to hypothesize that the effects of Dicer 
and TRBP on HCV replication are not solely due to endogenous miR-122 activities and 
levels.  
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Figure 3-3: Knockdown Dicer and TRBP did not affect endogenous miR-122 levels 
Endogenous miR-122 amounts were measured by qRT-PCR at 72 h p.s.e. Human U6 snRNA was 
used as an endogenous control. Values are expressed as fold of control siRNA sample. 
 
3.4 Knocking down Dicer and TRBP had no effects on HCV translation 
The results described above indicate that Dicer and TRBP facilitate HCV 
replication, but leave unresolved the mechanism by which this occurs. A previous report 
showed that miR-122 stimulates HCV translation through interacting with two seed-
sequence binding sites in the 5’UTR (Henke, et al., 2008). Thus, it is possible that the 
impaired HCV replication observed following Dicer and TRBP knockdown stems from a 
requirement of Dicer and TRBP functions in HCV translation and replication mediated 
by miR-122.  
To explore the possibility that disrupting Dicer and TRBP expression could 
potentially impair HCV translation and thus viral protein synthesis at early times of HCV 
infection, we designed HCV translation assays to monitor the effects of knocking down 
Dicer and TRBP on HCV translation. Experimental approaches were similar to the 
transient HCV replication assay, except a replication-defective genome full length 
J6/JFH-1-RLuc-GNN was used as a model for studying viral translation activity. Briefly, 
Dicer and TRBP were pre-knocked down by 60 mM siRNAs 3 days before a second 
electroporation. On the second electroporation, cells were co-electroporated with the 
same amount of siRNAs, 1 µg a capped Firefly Luciferase (FLuc) reporter and 5 µg 
J6/JFH-1-RLuc-GNN HCV RNA.  The FLuc reporter was used to analyze global effects 
in capped translation and RLuc was used to analyze the levels of HCV IRES translation, 
and the ratio of RLuc/FLuc indicates the relative level of HCV translation normalized to 
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the levels of total cellular translation. Cell lysates were harvested at 3.5 h, 4 h, and 4.5 h 
p.s.e. Ratios of RLuc to FLuc expression  indicated that decreasing Dicer and TRBP 
expression had no significant effects on transient HCV translation at each time point 
when compared with capped translation (Figure 3-4A). To exclude that relative reporter 
RNA levels contributed to HCV transient translation efficiency, HCV RNA and FLuc 
mRNA amounts were measured by qRT-PCR at 4 h p.s.e. No significant changes in the 
ratio of HCV/FLuc RNA were observed among the samples (Figure 3-4B). SiRNA 
efficacy was also tested by qRT-PCR at 4 h p.s.e. (Figure 3-4C). In addition, cell 
viabilities were similar in each sample as measured by WST-1 assay at 24 h p.s.e. (Figure 
3-4D). Taken together, the data indicated that knocking down Dicer and TRBP had no 
effects on transient HCV translation. Therefore, the striking reductions in HCV 
replication, as measured by RLuc expression and Northern blots following  Dicer and 
TRBP knock-down cannot  be attributed to their effects on IRES directed translation in 
the presence of miR-122. Human Dicer and TRBP facilitate HCV infection mainly 
through their functions exerted on HCV replication.  
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Figure 3-4: HCV Translation assay following siRNA knock-down of Dicer and 
TRBP. 
(A). Knocking down Dicer and TRBP did not affect HCV transient translation. Standardized 
RLuc/FLuc values for each sample were normalized against control siRNA. Cell lysates were 
harvested at 3.5 h, 4 h, and 4.5 h p.s.e. 
 (B). HCV RNA and FLuc reporter mRNA amounts were measured by qRT-PCR at 4 h p.s.e. 
with HCV and FLuc specific RT primer, as well as RLuc and FLuc specific qPCR primers 
(Jopling et al., 2008). Standardized RLuc/FLuc values for each sample were normalized against 
control siRNA. The gene expression study was analyzed by CFX 96 TM system (Bio-RAD) using 
ΔΔCt method.  
(C) Dicer and TBRP mRNA levels were measured by qRT-PCR at 4 h p.s.e. (D). Cell viabilities 
in parallel samples were measured by WST-1 assay at 24 h p.s.e.  
 
3.5 The effects of Dicer and TRBP on HCV replication are not solely due to miR-
122 biogenesis, and may be due to RISC loading. 
Our previous data showing that miR-122 levels did not decrease substantially in 
our transient HCV replication assays following Dicer and TRBP knockdown. This 
suggested that miR-122 levels were not responsible for reduced HCV replication. To 
confirm that the decrease in HCV replication is not due to reduced miR-122 levels caused 
by reduced miR-122 biogenesis following Dicer and TRBP knock-down, we created a 
mutant virus, with which replication of the virus is independent of endogenous miR-122, 
and dependent on a exogenously provided mutant miRNA. Using this system we can 
study the effects of Dicer and TRBP knockdown on HCV replication independent of any 
induced changes in endogenous miR-122 levels. For this assay, we used information from 
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Jopling et al. to design a mutant HCV genome in which the miR-122 binding site seed 
sequences had been altered.  Their group had successfully showed that exogenous mutant 
miR-122 (miR-122p3-4) could restore H77c (genotype 1a) RNA accumulation of 
genomes containing complementary mutations in the miR-122 seed binding sequences in 
the virus 5’UTR (Jopling, et al., 2006; Jopling, et al., 2008). Thus we mutated the 
nucleotides at positions 3 and 4 of each miR-122 seed sequence on the HCV genome (i.e., 
U26C to A27G and U41C to A42G) to yield J6/JFH-1-RLuc-m3-4 (Figure 3-5A), such 
that the mutant sites are not predicted to bind wt miR-122. We also synthesized  a mutant 
miR-122p3-4 duplex, whose sequence matches the mutant binding sites on J6/JFH-1-
Rluc-m3-4 such that base pairing will be restored between the miRNA and the HCV 
genomic RNA   (Figure 3-5B).  In this system, the effects of gene knockdown on HCV 
replication are thus independent of any possible effects on the biogenesis, and thus 
changes in the miR-122 levels in the cell.          
Using this system, we observed that the RLuc expression from cells 
electroporated with J6/JFH-1-RLuc-m3-4 and control miRNA was similar to that of 
J6/JFH1-RLuc-GNN confirming that J6/JFH-1-RLuc-m3-4 cannot replicate without the 
addition of a complementary miRNA. Addition of miR-122p3-4 to cells electroporated 
with J6/JFH-1-RLuc-m3-4 stimulated HCV RLuc levels to about 10% of that seen with 
wild type virus (data not shown). Thus replication of the mutant HCV genome is 
dependent on binding of the mutant miR-122p3-4. The level of RLuc expression 
expressed by this sample was deemed 100%. Knocking down Dicer attenuated miR-
122p3-4 complemented J6/JFH-1-RLuc-m3-4 RLuc expression levelsn by 52.71% on day 
3 p.e., and knocking down TRBP had a moderate impact on Luciferase expression, 
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decreasing it by 24.59% on day 3 p.e. (Figure 3-5C). Cell viability was tested by WST-1 
assay and did not change significantly between samples (Figure 3-5D). Therefore these 
results further support our hypothesis that the roles of Dicer and TRBP in HCV 
replication are not soley due to miR-122 biogenesis activity. Dicer and TRBP may be 
required for RISC assembly or for an effector step of miR-122 guided HCV 
augmentation. However, we cannot rule out other possible interpretations for the results 
described above. For example, it is possible that knocking down Dicer and TRBP could 
block the biogenesis of another miRNA having a role in HCV replication. Alternatively, 
there might exist another functional binding site for miR-122 on the HCV genome.  
 
 
(A)                                                         (B)   
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Figure 3-5:  HCV replication assay independent of endogenous miR-122 and miR-
122 biogenesis. 
(A): Schematic illustration of two miR-122 binding seed sequences in the 5’ UTR of HCV 
genome, a 7-nucleotide sequence (5’ACACUCC3’) and a 6-nucleotide sequence (5’CACUCC3’) 
(underlined and presented in bold). Nucleotides at positions 3 and 4 (UC) of each seed sequence 
were mutated to AG to yield J6/JFH-1-RLuc-m3-4.  
(B): Sequences of wt miR-122 and miR-122 p3-4 harboring complimentary mutations were 
commercially synthesized. Mutations were underlined and presented in bold. 
(C): Knocking down Dicer and TRBP attenuates J6/JFH-1-RLuc-m3-4 replication complemented 
by miR-122p3-4. Values were graphed from three independent experiments and expressed as fold 
of J6/JFH-1-RLuc-m3-4 + miR-122m3-4 + control siRNA treated sample at each time point. 
Samples were harvested at 1 h, and day 3 p.e. 
(D). Cell numbers in each sample were measured by WST-1 assay at day 3 p.e. Viable cell 
numbers were expressed as fold of J6/JFH-1-RLuc-m3-4 + control miRNA treated sample. 
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4.0 DISCUSSIONS 
      4.1 Dicer and TRBP are essential for post-transcriptional regulation of miRNA 
activity and contribute to HCV replication. 
To elucidate the interaction between the host miRNA pathway and virus 
replication, previous studies have indicated that host miRNA, miR-122 and miRNA 
effector proteins, Argonaute 1-4, influence HCV replication (Norman, et al., 2010; 
Randall, et al., 2007).  In this work, we proposed a model, in which mature miR-122 is 
incorporated into a ribonucleoprotein complex, similar to RISC, with the minimum 
constitution of miR-122 and Ago2, and miR-122 promotes HCV replication and 
translation through the cooperation with this complex (Figure 4-1).  For this study we 
were interested in the roles of Dicer and TBPR, proteins that function upstream of Ago2 
in the miRNA pathway, and presumably in HCV replication (Figure 4-1).  In our study, 
we found that knockdown of human Dicer or TRBP (Figure 3-1 A, B, C), impeded HCV 
replication in human liver cells (Figure 3-2A, B, C) but did not affect virus translation 
(Figure 3-4A, B, C) or cellular proliferation (Figure 3-4D). Because Dicer and TRBP are 
involved in miRNA biogenesis, their knockdown is predicted to transiently block the 
miR-122 processing pathway. However, disrupting endogenous Dicer or TRBP did not 
greatly affect total amounts of miR-122 in Huh 7.5 cells (Figure 3-3).  These data suggest 
that the half life of miR-122 is long enough that sufficient quantities are still present 
following 5 days of Dicer and TRBP knockdown.  These data also suggest that Dicer and 
TRBP facilitate HCV replication in a way other than solely through their roles in miR-
122 biogenesis. To further support this hypothesis, we designed an experiment in which 
HCV replication is dependent on an exogenously provided mutant miRNA. Thus this 
58 
 
assay bypasses the requirement for Dicer and TRBP in miR-122 biogenesis. For this 
experiment we introduced mutations to miR-122 seed-sequence binding sites in the 
5’UTR of HCV (J6/JFH-1-RLuc m3-4) genome in order to prevent wt miR-122 binding 
(Figure 3-5A, B). The RNA abundance of mutant HCV genome (m3-4) can be restored 
by introducing a mutant miR-122 bearing complimentary mutations (miR-122p3-4). If 
Dicer or TRBP are required for activities other than miR-122 biogenesis then their 
knock-down will still affect HCV replication in this assay. What we found was consistent 
with our hypothesis: knocking down Dicer decreased miR-122p3-4 complemented 
J6/JFH-1 RLuc m3-4 replication 52.71% on day 3 p.e., and siTRBP attenuated this 
complementation process by 24.59% on day 3 p.e. (Figure 3-6 C, D). Our findings 
indicate that Dicer and TRBP are not only responsible for miR-122 biogenesis, but may 
also be involved in the activity of miR-122 in stimulating HCV replication, perhaps 
through the assembly of active and functional miR-122 containing RISC complex (Wang, 
et al., 2009; Jaskiewicz, et al., 2008; Gregory, et al., 2005).  However, we cannot exclude 
the possibility that the effects of Dicer or TRBP knockdown in this assay are indirect, 
such as via reguation of the biogenesis of a miRNA other than miR-122 that may 
positively influence HCV replication, or through disregulation of a host gene that 
contributes to HCV replication. However, these data support our hypothesis that Dicer 
and TRBP function to augment HCV replication through roles in both miR-122 
biogenesis and through roles downstream of miR-122 biogenesis, most likely in the 
loading of miR-122 into the RISC complex. This also suggests that the protein complex 
responsible for miR-122 augmentation of HCV replication has a minimum composition 
of Argonaute and Dicer, and TRBP.  
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Figure 4-1: Schematic model for HCV replication assay independent of miR-122 
binding and miR-122 biogenesis. The replication of J6/JFH-1-RLuc m3-4  relies on the 
complementation of miR-122 p3-4, as well as the possible involvement of Dicer and 
TRBP. 
 
The roles of Dicer and TRBP in miRNA biogenesis have been well established 
(Hutvagner, et al., 2001; Cullen, et al., 2004; Chendrimada, et al., 2005; Jaskiewicz, et 
al., 2008). TRBP is required for efficient cleavage of pre-miRNA in vitro (Haase, et al., 
2005).  It also assists in the miRNA processing function of Dicer through interaction with 
its C4 sequence within the Medipal domain in mammalian cells (Daniels, et al., 2009).  
Overexpression of TRBP1 or TRBP2 but not TRBPΔC4 in Tarbp2 -/-cells was able to 
rescue processing of shRNAs or exogenous microRNAs (Daniels, et al., 2009). However, 
TRBP also has a role in assembly of the RISC.  It is proposed to act as a sensor to detect 
proper loading of the 3’end of the guide strand onto the Ago2 PAZ domain and it also 
functions to orient the guide strand for direct handoff to Ago2 (Castanotto, et al., 2007; 
Wang, et al., 2009). TRBP recruits Dicer complex to Ago2 for microRNA processing and 
gene silencing (Chendrimada, et al., 2005).  Thus in the process of miR-122 
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augmentation of HCV replication, TRBP may also function to enhance miR-122 loading 
into Ago containing RISC. 
Dicer is also thought to contribute to the process of RISC assembly.  RISC is able 
to incorporate a Dicer-processed miRNA hairpin more effectively than a 21nt exogenous 
and synthetic miRNA duplex, supporting the contention that Dicer cleavage function is 
tightly related to the RISC loading step of miRNA gene suppression mediated by RISC 
(Gregory,  et al.,  2005). It has been proposed that Ago2’s Piwi domain and Mid domain 
interact with Dicer’s platform and Ago2’s N-terminal domain interacts with Dicer’s base 
branch density during assembly of the miRNA machinery. Furthermore, the distance 
between the PAZ domains of Ago2 and Dicer allows a perfect accommodation of the 
22nt siRNA, achieving a siRNA-bound intermediate (Wang, et al., 2009). 
In miRNA directed translation suppression the active human RISC was shown to 
be composed of three proteins, Dicer, TRBP and Ago2 (Gregory, et al., 2005).   The 
Dicer–TRBP complex may be not only involved in miRNA processing but also as a 
platform for RISC assembly.  Depletion of the Dicer–TRBP complex via exogenously 
introduced siRNAs resulted in a diminished siRNA-mediated Firefly Luciferase mRNA 
silencing (Chendrimada, et al., 2005; Doi, et al., 2003).  The luciferase specific siRNAs 
did not require processing, thus the diminished silencing activity is thought to be due to 
inefficient RISC assembly. However, evidence suggests that Dicer might merely play a 
stimulatory role in the assembly and function of the mammalian RISC. One report 
favored that Dicer may disassociate from RISC after loading of miRNA and that Ago2 
bound with miRNAs may form a functional miRNA ribonucleoproteins (miRNPs) 
complex by associating with other proteins without Dicer (Maniataki, et al., 2005). 
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Moreover, following immunodepletion of Dicer, cells are still capable of retaining 
siRNA-mediated RISC activity (Martinez, et al.,  2002), and Dicer knock-out mouse 
embryonic stem cells are able to perform RNAi in response to exogenous siRNAs 
(Kanellopoulou, et al., 2005).  
In our studies, although endogenous miR-122 amounts were not strongly reduced 
by knocking down Dicer and TRBP at 72 h p.s.e., these results do not contradict the 
miRNA biogenesis functions of Dicer and TRBP, since other miRNA levels may have 
decreased, and miR-122 may persist in the cell independent of newly synthesized miRNA.  
Our model for the function of TRBP and Dicer in miR-122 augmentation of HCV 
replication is in RISC assembly. We speculate that human TRBP may proofread the 
strand specificity and transfer the guide strand of miR-122 to RISC. Human Ago2 would 
associate with Dicer to accommodate miR-122 in a miRNA bound miRNP intermediate. 
Therefore, knockdown of Dicer or TRBP could result in inefficient or incorrect RISC 
assembly and dysfunction of miR-122 bound RISC.  Previous reports have shown that 
knocking down either Dicer or TRBP destabilizes the associations with each other but not 
with Ago2 (Chendrimada, et al., 2005), thus knocking down either Dicer or TRBP may 
abolish the activity of both proteins in the complex. Therefore Ago2 together with 
miRNA might be the minimum active and functional RISC in miR-122 augmentation of 
HCV replication.    
Our data showed that Dicer and TRBP did not affect HCV translation activity.  
However, miR-122 has been shown to stimulate HCV translation by direct interaction 
with two binding sites in 5’UTR of HCV genome which enhances the association of 
ribosomal 48S initiation complexes and 80S ribosomes with HCV RNA (Niepmann et al., 
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2010). Our data suggest that Dicer and TRBP may be dispensable for the miR-122 
stimulation of HCV translation. But that Ago2 is involved in miR-122 stimulation of 
HCV translation (unpublished). Therefore, it appears that the minimum functional RISC 
required for miR-122 stimulation of translation is probably composed of Ago2 and 
miRNA.  
 
      4.2 Dicer may have competing roles when modulating HCV replication 
RNAi has been shown to be a major component of the innate immune responses 
to viral infections in both plants and invertebrates. All RNA viruses (except retroviruses) 
and many DNA viruses are able to produce large amount of long, perfect dsRNA 
molecules in infected cells, which are recognized by cytoplasmic RNAse III Dicer as 
foreign.  Double stranded RNA can trigger an RNAi response to generate siRNAs of viral 
origins, which are then used by the siRNA machinery to inhibit virus replication (Cullen, 
et al.,  2006).  However, it remains unclear whether RNAi is involved in antiviral defense 
in mammalian cells. Since initial processing of cellular miRNA occurs in the nucleus by 
RNAse III Drosha, it is suggested that only viruses that replicate in the nucleus will be 
able to generate miRNAs. So far, evidence has failed to prove the existence of miRNAs 
derived from RNA viruses such as yellow fever virus and HCV in mammalian cells, 
(Pfeffer, et al.,  2005).  Several DNA viruses, such as Simian Polyomavirus 40 (SV40), 
Herpes Simplex Virus-1 (HSV-1) and Epstein - Barr virus (EBV) (Cullen, et al.,  2006), 
were found to encode miRNA molecules in infected cells and these miRNAs are thought 
to help viruses establish long-term latent infections and reshape the cellular environment 
to maximize viral replication. 
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    It is well established that cellular miRNAs play important roles in the regulation of 
cellular genes. Recent studies indicate cellular miRNAs may also have a substantial 
effect on the viral life cycle and may continue to influence the in vivo tissue tropism of 
viruses. Cellular miR-199 was proposed to target domain II of the IRES region in the 
HCV5’ UTR and inhibit HCV infection (Murakami, et al., 2009). In addition, 8 INF-β 
induced cellular miRNAs were found to antagonize HCV replication and infection, 
suggesting that mammals may employ cellular miRNAs to combat viral infections 
through the interferon system (Pedersen, et al.,  2007). In addition, it has been shown that 
the HCV core protein inhibits Dicer (Chen, et al., 2008; Wang, et al., 2006).  However, if 
miRNA suppression of HCV replication was a strong effect in infected cells, then 
knockdown of Dicer would have caused an increase in HCV replication, instead we saw a 
decrease.  These data suggest that miR-122 augmentation of HCV replication is dominant 
to any possible suppressive effect of endogenous miRNAs on HCV.  However, we cannot 
exclude the possibility that the short duration of Dicer knock-down may not have reduced 
the levels of antiviral miRNA to such an extent that they affect HCV replication.   
It has also been suggested that HCV RNA itself might be a substrate for Dicer.  HCV 
IRES and its isolated domains II, III and VI were shown to be substrates and be 
recognized by recombinant human Dicer cleavage in EMSA experiments in vitro (Ouellet, 
et al., 2009).  HCV does not appear to elicit a RNAi response, since no miRNAs/siRNAs 
derived from HCV could be detected among 1318 small RNA sequences isolated from 
the HCV-infected Huh7.5 cell lines, and Dicer did appear to bind HCV IRES in 9-13 and 
Huh-7 cells, (Pfeffer, et al., 2005; Ouellet, et al., 2009).  It has been suggested that HCV 
adopts a structure refractory to Dicer processing and that this resistance is modulated by 
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miR-122.  MiR-122 was shown to induce conformational changes within the HCV IRES, 
when confronted with E. coli RNase III cleavage in vitro. miR-122 binding disfavors 
closed ‘circular’ conformation ‘C’, base paired by nt 24-38 and nt 428-442 in the core 
coding region (which forms long-range annealing (LRA) motif) to an open ‘O’ form 
(where bases 428–442 interact with bases 494–508 to form stem-loop VI) , which is less 
prone to RNase III cleavage (Beguiristain, et al.,  2005; Diaz-Toledano, et al.,  2009). 
Therefore, it is possible that miR-122 binds to 5’ UTR of HCV genome to prevent the 
formation of LNA and further diverts Dicer to the core coding region, which is assumed 
to be less prone to Dicer processing. According to two published reports, overexpression 
of HCV core protein can antagonize RNA silencing and rescue HCV replication by direct 
interaction with Dicer (Chen, et al., 2008; Wang, et al.,  2006); therefore, the HCV core 
protein could interfere with Dicer processing of HCV RNA. In addition, viral and cellular 
proteins interacting with the HCV IRES are likely to further limit the accessibility to 
Dicer processing in vivo. We propose that two possible ways might co-exist for human 
Dicer to both positively and negatively modulate HCV infection: i) promoting HCV 
replication through the activity of miR-122; ii) Suppressing HCV replication through the 
generation of anti-viral siRNAs, or host miRNAs, such as miR-199a (Murakami, et al., 
2009). However, the requirement of Dicer in miR-122 mediated RNAi for HCV 
replication must be dominant over any antiviral activity exerting against HCV since 
depletion of Dicer impairs HCV replication in Huh7.5 cells.  It is possible that an 
antiviral function for Dicer might become dominant following IFN-β/γ treatments 
(Pedersen, et al., 2007).  
 
65 
 
      4.3 TRBP is an inhibitor of PKR induced antiviral pathways 
In addition to its roles in miRNA biogenesis and as part of the RISC complex, 
TRBP also binds to and inactivates the interferon (IFN)-stimulated dsRNA-activated 
protein kinase (PKR) (Daher, et al., 2001).  The IFN-induced cellular antiviral cascade is 
the first defense against viral infection within an animal host. Interferon stimulation 
activates several antiviral pathways, one of which is the PKR pathway. Activation of 
PKR restricts viral replication through its ability to phosphorylate the alpha subunit of the 
eukaryotic initiation factor 2 (eIF-2α), resulting in a block to further cellular and viral 
translation (Gale, et al., 1998). In order to establish a productive infection, viruses must 
overcome IFN-induced blocks imposed on viral replication.  
PKR was shown as a key mediator of IFN action against HCV. Elevated PKR 
expression was reported in HCV infected hepatoma tissues and animal models (Daniels, 
et al.,  2009) and HCV replicates more efficiently in (PKR–/–) MEF (Chang, et al.,  2006). 
It is well documented that HCV employs several strategies to counteract the antiviral 
effects of IFN; among them, HCV IRES, NS5A and E2 function to antagonize the 
translation-inhibiting function of PKR. Garaigorta et al. (2009) proposed that PKR 
activation and eIF-2α phosphorylation prevent protein synthesis of antiviral interferon-
stimulated gene (ISGs) expression in the liver, but not HCV proteins. HCV-IRES was 
suggested to escape eIF-2α phosphorylation by recruiting ribosomes to initiate translation 
and bypass the hydrolysis of GTP by eIF2 (Shimoike, et al., 2009). HCV NS5A and E2 
proteins were shown to inhibit PKR-activation by binding “PKR-binding domain” of 
NS5A and PKR/eIF-2α phosphorylation homologous domain (PePHD) of E2. These may 
consequently release the inhibition of both cap- and HCV IRES-dependent translations 
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and permit infected cells to maintain persistent growth and infection that are 
characteristic of HCV (Gerotto, et al., 2000). 
In addition to its role in the process of miRNA gene suppression activity 
(Chendrimada, et al., 2005; Daniels, et al.,  2009), TRBP also interacts with PKR and 
blocks its inhibitory effect on HIV replication (Ong, et al., 2005; Daher, et al., 2001).  
Therefore, it is possible that TRBP knockdown attenuates HCV replication through 
activation (or de-inhibition) of PKR. However, our data does not support this notion since 
knock down of TRBP did not affect HCV translation and global cap-dependent 
translation (Figure 3-5). 
We also speculate that TRBP might bind to the HCV IRES.  It is known that 
TRBP binds to double stranded RNA, and binds to the highly structured TAR RNA of 
HIV.  HCV-IRES was mapped to have high-affinity PKR-IRES RNA interaction to stem-
loops III-IV (Shimoike, et al.,  2009), which led us to hypothesize that this region might 
also bind TRBP.   If this is the case then TRPB could protect HCV from PKR by 
competitive binding to the structured HCV RNA. In addition, as discussed above, the 
HCV IRES may have evolved to escape Dicer processing in vivo.  We propose that HCV 
may also divert TRBP from Dicer to avoid RNAi antiviral function and guarantee 
effective viral replication.  Alternatively, HCV and human liver cells would have co-
evolved with favoring HCV replication by predominantly producing miR-122 over other 
antiviral cellular miRNAs and virus-derived miRNAs processed by Dicer and TRBP. 
Therefore, we would like to follow up our studies by further investigating the 
mechanisms of TRBP modulation of HCV replication, and determine if it functions 
through the RNAi machinery or PKR, or both. To test this hypothesis, we will measure 
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the levels of phosphorylation of PKR in transient HCV replication assay experiments 
following siRNA knockdown of TRBP.  Phosporylated PKR and eIF-2α protein levels 
could be detected by Western Blot using specific antibodies.  We could also determine if 
the decrease to HCV replication by knockdown of TRBP is dependent on PKR.  We 
hypothesize that knockdown of PKR would likely enhance HCV replication.  If TRBP 
knockdown does not attenuate HCV replication in the absence of PKR, then we can 
conclude that the effects of TRBP on HCV are through the activity of PKR.   To confirm 
the interaction of PKR and TRBP in HCV infected cells we could study the interaction of 
TRBP and PKR in HCV-infected Huh7.5 cells by co-immunoprecipiation and co-
localization.  The second strategy could be pursued by monitoring the effects of 
overexpressed TRBP upon HCV replication or translation, compared with a control 
plasmid. As for HIV, a small increase in the expression of TRBP has been shown to 
counteract the inhibitory effects of PKR on HIV-1 LTR-driven protein expression and on 
HIV-1 viral replication in astrocytoma cells (Gatignol, et al.,  1991; Ong, et al., 2005). 
Thus we will measure HCV RNA replication and viral protein expression stimulated by 
TRBP in a dose dependent manner, and determines the optimum levels of TRBP 
expression in Huh7.5 cells.  
It is also possible that TRBP binds to the HCV genomic RNA since it is a dsRBD 
protein.  Thus we also propose to study the interaction of TRBP and HCV genome by a 
mobility shift assay, or RNA immunoprecipitation assay, and further map the specific 
domains for the protein and viral RNA interaction.  If TRBP binds to the HCV genome 
then we speculate that TRBP could potentially compete with PKR for HCV genome 
binding. 
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Similarly, another target for a study on its role in modulating HCV replication is 
PKR Activating Protein (PACT).  Similar to TRBP, PACT is a dsRBD protein identified 
to bind to Dicer and TRBP and facilitate miRNA biogenesis and RISC loading.  
Converse to TRPB which binds to, and inactivates PKR, PACT binds and activates PKR 
(Kok, et al., 2007). PACT heterodimerizes with PKR/TRBP through its dsRBDs and 
Medipal domain and enhances PKR induced antiviral defense (Patel, et al.,  1998). 
However, under certain stress conditions, such as arsenite, peroxide and serum starvation-
mediated stresses, the TRBP-PACT interaction was dissociated  and the released PACT 
was free to further augment PKR phosphorylation (Daher et al.,  2009). Therefore, it also 
deserves investigation to unravel PACT’s dual roles involved in RNAi mechanism and 
INF-PKR pathway and how this protein might also influence HCV replication. 
To the best of our knowledge, this is the first study that links TRBP and Dicer 
with HCV replication and translation. Therefore, TRBP and Dicer could potentially 
become novel cellular targets for therapeutic interventions to block productive HCV 
replication in cells that are fully permissive for HCV infection. 
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5.0 FUTURE DIRECTIONS 
          Our study highlighted the potential of siRNA technology to identify multiple 
candidate proteins in RISC, such as Dicer, TRBP, Ago2, PACT and FXMR (an mRNA-
binding protein involved in the pathogenesis of fragile X syndrome, has been shown to 
interact with Dicer and Ago-1 in mammalian cells (Jin, et al., 2004) which modulate HCV 
replication and translation through miR-122 guided RNAi machinery. Our model system 
also preliminarily provided the groundwork for differentiating the identities of potential 
factors involved in the areas of miRNA biogenesis and major players functioning in the 
effector steps of RNAi machinery.  
          Future work will focus on determining if TRBP and Dicer physically associate with 
the HCV 5’UTR RNA sequences through miR-122 guided RISC binding.  We plan to 
isolate RISC proteins by using biochemical methods such as immunoprecipiation to 
determine if TRBP and Dicer associate with HCV RNA.  In addition, we will use the 
mobility shift assay or RNA immunoprecipitation assay to study the binding of Dicer and 
TRBP with HCV 5’UTR RNA.   In addition, further investigation will be carried out to 
map the RNA sequence elements required for the protein binding by site directed 
mutagenesis of the 5’UTR, including mutations to the miR-122 seed binding sites. We 
will also analyze the effects of Dicer and TRBP knockdown on the production of 
infectious virus by treating infected cells with siDicer and siTRBP and analyzing the 
virus production by titration using a fluorescent focus forming assay. Based on these 
approaches, we will deepen and broaden our knowledge of specific roles of RISC 
proteins involving modulating HCV infection and explore novel antiviral targets.  
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